Effect of natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn's disease-a pilot study

Free Radical Research

Volumn 47, Issue 8, 2013, Pages 624-634

  Kolacek M ^a,b   Muchova J ^a   Dvorakova M ^a   Paduchova Z ^a   Zitnanova I ^a   Cierna I ^c   Orszaghova Z ^a   Szekyova D ^c   Jajcaiova Zednickova N ^c   Kovacs L ^c   Durackova Z ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b University Teaching Hospital in Martin   (Slovakia)

^c University Children's Hospital Bratislava   (Slovakia)

Author keywords

Antioxidant enzymes; Calprotectin; Crohn's disease; Diamine oxidase; Iron metabolism; Oxidative stress; Pycnogenol

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); C REACTIVE PROTEIN; CALGRANULIN; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; PYCNOGENOL; SUPEROXIDE DISMUTASE;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; PILOT STUDY; REMISSION;

ADOLESCENT; AMINE OXIDASE (COPPER-CONTAINING); ANTIOXIDANTS; BIOLOGICAL MARKERS; CHILD; CROHN DISEASE; FEMALE; FLAVONOIDS; HUMANS; INFLAMMATION; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MESALAMINE; OXIDATIVE STRESS; PILOT PROJECTS;

EID: 84880528928     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.807508     Document Type: Article

References (59)

1. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999;13:65-73.
2. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-447.
3. Kappelman MD, Crandall WV, Colletti RB, Goudie A, Leibowitz IH, Duffy L, et al. A short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis 2011;17:112-117.
4. Sies H (ed.). Oxidative Stress: Oxidants and Antioxidants. London; San Diego: Academic Press; 1991. 650 p.
5. Suraková Z. Some current insights into oxidative stress. Physiol Res 2010;59:459-469.
6. Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, et al. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis 2008; 14:794-802.
7. Maor I, Rainis T, Lanir A, Lavy A. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig Dis Sci 2008;53:2208-2214.
8. Wendland BE, Aghdassi E, Tam C, Carrrier J, Steinhart AH, Wolman SL, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 2001;74: 259-264.
9. Phylactos AC, Fasoula IN, Arnaud-Battandier F, Walker-Smith JA, Fell JM. Effect of enteral nutrition on antioxidant enzyme systems and inflammation in paediatric Crohn's disease. Acta Paediatr 2001;90:883-888.
10. Krzystek-Korpacka M, Neubauer K, Berdowska I, Zielinski B, Paradowski L, Gamian A. Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment. Inflamm Bowel Dis 2010;16: 1467-1475.
11. Beltrán B, Nos P, Dasí F, Iborra M, Bastida G, Martínez M, et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease. Inflamm Bowel Dis 2010;16:76-86.
12. Iborra M, Moret I, Rausell F, Bastida G, Aguas M, Cerrillo E, et al. Role of oxidative stress and antioxidant enzymes in Crohn's disease. Biochem Soc Trans 2011;39:1102-1106.
13. Kruidenier L, Kuiper I, Lamers CBHW, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semiquantification, localization, and association with mucosal antioxidants. J Pathol 2003;201:28-36.
14. Romier B, Schneider YJ, Larondelle Y, During A. Dietary polyphenols can modulate the intestinal inflammatory response. Nutr Rev 2009;67:363-378.
15. Rohdewald PJ. Pycnogenol, French maritime pine bark extract. In: Coates P, Blackman MR, Cragg G, Levine M, Moss J, White J (eds.). Encyclopedia of Dietary Supplements. New York: Marcel Dekker; 2005. pp. 545-553.
16. Grimm T, Chovanová Z, Muchová J, Sumegová K, Liptáková A, Suraková Z, Högger P. Inhibition of NF-?B activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (London) 2006;3:1-6. Available at: http://www.journal-inflammation.com/content/3/1/1 via the INTERNET. Accessed 2006 Jan 27.
17. Schäfer A, Chovanová Z, Muchová J, Sumegová K, Liptáková A, ?ura?ková Z, Högger P. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2006;60:5-9.
18. Golaski J, Muchova J, Golaski R, Durackova Z, Markuszewski L, Watała C. Does Pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition of platelet function? In vitro experience. Postepy Hig Med Dosw (online) 2006;60:316-321. Available at: http://www.phmd.pl/pub/phmd/vol-60/ 9431.pdf via the INTERNET. Accessed 2006 June 23.
19. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol?), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40: 158-168.
20. MacKay D. Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev 2004;9:4-16.
21. Koch R. Comparative study of Venostasin and Pycnogenol? in chronic venous insufficiency. Phytother Res 2002; 16:S1-S5.
22. Križková L, Suraková Z, Kraj?ovi? J. Natural polyphenols possess antioxidative and antimutagenic properties. 8. mezioborová ?esko-slovenská toxikologická konference 2003 Sept 3-5 Praha. Praha: [s.n.], 2003; 128 p.
23. Belcaro G, Luzzi R, Cesinaro Di Rocco P, Cesarone MR, Dugall M, Feragalli B, et al. Pycnogenol® improvements in asthma management. Panminerva Med 2011;53:57-64.
24. Frontela-Seta C, López-Nicolás R, González- Bermúdez CA, Peso-Echarri P, Ros-Berruezo G, Martínez- Graciá C, et al. Evaluation of antioxidant activity and antiproliferative effect of fruit juices enriched with Pycnogenol® in colon carcinoma cells. The effect of in vitro gastrointestinal digestion. Phytother Res 2011;25:1870-1875.
25. Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Evaluation of the pediatric Crohńs disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-421.
26. Bergmeyer HU (ed.). Methods of enzymatic analysis. Volume 3. Enzymes 1: Oxidoreductases, transferases. 3rd ed. Weinheim; Deerfield Beach/Florida; Basel: Verlag Chemie; 1983. 605 p.
27. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 1999;26:1231-1237.
28. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989;30:627-630.
29. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007;52:2015-2021.
30. Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci 2004;49:1433-1437.
31. Tüzün A, Erdil A, Inal V, Aydin A, Baci S, Yeilova Z, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 2002;35:569-572.
32. Paduchová Z, Suraková Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy 2009; 110:598-602.
33. Wagner M, Peterson CGB, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-5589.
34. Henderson P, Casey A, Lawrence SJ, Kennedy NA, Kingstone K, Rogers P, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012;107:941-949.
35. Burri E, Beglinger C. Faecal calprotectin-a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 2012;142:w13557.
36. Mochizuki M, Hasegawa N. Therapeutic efficacy of Pycnogenol in experimental inflammatory bowel disease. Phytother Res 2004;18:1027-1028.
37. Rosillo MA, Sanchez-Hidalgo M, Cárdeno A, Alarcón de la Lastra C. Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's disease. Biochem Pharmacol 2011;82:737-745.
38. Suraková Z, Trebatický B, Novotný V, Žitanová I, Breza J. Lipid metabolism and erectile function improvement by Pycnogenol®, extract from the bark of Pinus pinaster in patients suffering from erectile dysfunction-a pilot study. Nutr Res 2003;23:1189-1198.
39. Chovanová Z, Muchová J, Sivo?ová M, Dvoáková M, Žitanová I, Waczulíková I, et al. Effect of polyphenolic extract, Pycnogenol®, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radic Res 2006;40:1003-1010.
40. Dvo?áková M, Sivo?ová M, Trebatická J, Škodá?ek I, Waczulíková I, Muchová J, ?ura?ková Z. The effect of polyphenolic extract from pine bark, Pycnogenol?, on the level of glutathione in children suffering from attention deficit hyperactivity disorder (ADHD). Redox Rep 2006;11: 163-172.
41. Cisár P, Jány R, Waczulíková I, Sumegová K, Muchová J, Vojtaššák J, et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytother Res 2008;22:1087-1092.
42. Dvořá M, Paduchová Z, Muchová J, ?ura?ková Z, Collins AR. How does Pycnogenol influence oxidative damage to DNA and its repair ability in elderly people? Prague Med Rep 2010;111:263-271.
43. Errichi BM, Belcaro G, Hosoi M, Cesarone MR, Dugall M, Feragalli B, et al. Prevention of post thrombotic syndrome with Pycnogenol® in a twelve month study. Panminerva Med 2011;53:21-27.
44. Peng YJ, Lee CH, Wang CC, Salter DM, Lee HS. Pycnogenol attenuates the inflammatory and nitrosative stress on joint inflammation induced by urate crystals. Free Radic Biol Med 2012;52:765-774.
45. Enseleit F, Sudano I, Périat D, Winnik S, Wolfrum M, Flammer AJ, et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a doubleblind, randomized, placebo-controlled, cross-over study. Eur Heart J 2012;33:1589-1597.
46. Viktorinova A, Trebaticka J, Paduchova Z, Ursinyova M, Uhnakova I, Masanova V, Durackova Z. Natural polyphenols modify trace element status and improve clinical symptoms of attention-deficit hyperactivity disorder. Biomed Pharmacother 2009. Available: http://www.sciencedirect.com/science?-ob- ArticleURL &-udi-B6VKN-4XGXKSV-2&-user-5674000&-coverDate- 10%2F20%2F2009&-rdoc-1&-fmt-high&-orig-search&-origin- search&-sort-d&-docanchor-&view-c&-acct-C000053045&-version- 1&-urlVersion-0&-userid-5674000&md5-09 84b1b08367c2693936ebc45e5ecd33&searchtype-a via the INTERNET. Accessed 2009 Oct 20.
47. Sivo?ová M, Žit?anová I, Horáková ?, Štrosová M, Muchová J, Balgavý P, et al. The combined effect of Pycnogenol with ascorbic acid and trolox on the oxidation of lipids and proteins. Gen Physiol Biophys 2006;25: 379-396.
48. Kolá?ek M, Muchová J, Vranková S, Jendeková L, Pechá?ová O, Uli?ná O, et al. Effect of natural polyphenols, Pycnogenol® on superoxide dismutase and nitric oxide synthase in diabetic rats. Prague Med Rep 2010;111: 279-288.
49. Maritim A, Dene BA, Sanders RA, Watkins JB III. Effects of Pycnogenol treatment on oxidative stress in streptozotocininduced diabetic rats. J Biochem Mol Toxicol 2003;17: 193-199.
50. Parveen K, Khan MR, Mujeeb M, Siddiqui WA. Protective effects of Pycnogenol® on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interact 2010;186:219-227.
51. Yang YS, Ahn TH, Lee JC, Moon CJ, Kim SH, Jun W, et al. Protective effects of Pycnogenol® on carbon tetrachlorideinduced hepatotoxicity in Sprague-Dawley rats. Food Chem Toxicol 2008;46:380-387.
52. Rieth AG, Baader SL, Lode HN, Bruchelt G, Niethammer D. Ferritin enhaces production of DNA strand breaks by 6-hyroxydopamine, scorbic acid and H2O2 in CCC PM2 bacteriophage DNA. BioMetals 1992;5:223-227.
53. Halliwell B, Gutteridge J. Free radicals in biology and medicine. 4th ed. Oxford, New York: Oxford University Press; 2010. 851 p.
54. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr 2007;85:1185-1196.
55. Schmidt WU, Sattler J, Hesterberg R, Röher HD, Zoedler T, Sitter H, Lorenz W. Human intestinal diamine oxidase (DAO) activity in Crohn's disease: a new marker for disease assessment? Agents Actions 1990;30:267-270.
56. Thompson JS, Burnett DA, Vaughan WP. Factors affectin plasma postheparin diamine oxidase activity. Dig Dis Sci 1991;36:1582-1588.
57. Honzawa Y, Nakase H, Matsuura M, Chiba T. Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability. Inflamm Bowel Dis 2011;17:E23-E25.
58. Choi YH, Yan GH. Pycnogenol inhibits immunoglobulin E-mediated allergic response in mast cells. Phytother Res 2009;23:1691-1695.
59. Sharma SC, Sharma S, Gulati OP. Pycnogenol inhibits the release of histamine from mast cells. Phytother Res 2003; 17:66-69.